🧠 Brief Summary
Scientists at Johns Hopkins Medicine have managed to develop small models of brain tissue called brain organoids using blood cells from Alzheimer’s patients. These models showed a distinctive ability to predict how different types of Alzheimer’s patients would respond to a specific psychiatric treatment, namely an antidepressant from the selective serotonin reuptake inhibitors (SSRIs) class, opening the door to identifying more precise personalized treatments. In addition, the research showed that these models release tiny particles called extracellular vesicles that carry biological markers that could one day be used to diagnose the disease and measure its progression.
🩺 Introduction: Developing Miniature Brain Models to Understand Alzheimer’s
Alzheimer’s disease is the most common form of dementia, affecting millions of people around the world. Despite intensive research, treating the disease remains a challenge, especially because of the wide variation in patients’ responses to accompanying psychiatric treatments. In this context, a research team from Johns Hopkins Medicine created “mini brain organoids” from laboratory brain tissue derived from Alzheimer’s patients’ blood cells.
These models represent a miniature version of a part of the brain called the hindbrain, which is responsible for vital functions such as breathing, sleep, and controlling heartbeats. The main goal of these models is to test the response of brain tissue to a specific psychiatric treatment and monitor the molecular changes associated with it.
🧬 How Were These Brain Models Made?
The researchers began by collecting a blood sample from Alzheimer’s patients, numbering many participants, as they reprogrammed the blood cells into stem cells called induced pluripotent stem cells (iPSCs). These cells are distinguished by their ability to transform into any type of cell in the body.
These stem cells were directed to develop into reticular tissues in the hindbrain region containing nerve cells that produce the neurotransmitter serotonin, which is the primary target of antidepressant treatment. These cells come together to form grain-sized clusters known as organoids that mimic the basic structure and function of the brain.
🩺 The Importance of Using Patients’ Original Cells
By relying on real blood cells from Alzheimer’s patients, the models became more accurate in simulating molecular disease changes, which enhances the possibility of using these tools in personalized studies that align with biological differences between patients.
🧪 Molecular Changes Revealed by Alzheimer’s Models
The organoids derived from Alzheimer’s patients showed clear changes in proteins involved in:
- communication between brain cells
- neuroinflammation
- different pathways linked to the disease progression of Alzheimer’s
Compared with models derived from healthy people, Alzheimer’s patients’ models showed a decrease in the levels of vital proteins such as RAB3A, NSF, and ATCAY, known for their roles in normal neural signaling.
🩺 Testing the Response to the Antidepressant
The research team exposed these laboratory tissues to an antidepressant from the SSRIs class known as escitalopram oxalate. In some patient models, a noticeable increase was observed in proteins adapted to improve signaling in the serotonin system, suggesting a better readiness to improve psychiatric symptoms such as anxiety and depression.
By contrast, some samples showed no noticeable changes in protein levels despite treatment, reflecting the diversity of response among patients with the same condition.
🧠 The Role of extracellular vesicles in Evaluation and Diagnosis
Another distinctive feature of the miniature brain models is their ability to secrete tiny particles known as extracellular vesicles. These vesicles carry vital cellular information, including proteins that contribute to brain functions such as communication between neurons, memory, and neurotransmitter release.
The researchers examined these particles before and after drug treatment and noticed changes in certain proteins associated with serotonin pathways and neural communication. This suggests the possibility of using these vesicles as biomarkers that help with:
- diagnosing the stage of disease progression
- predicting the response to different treatments
🩺 The Potential Benefits of Using the Model’s Vesicles as a Liquid-Biopsy-Like Test
This technique could allow for early, precise, non-invasive evaluations of a patient’s condition, which may open new horizons in improving disease management through accurate characterization of the disease profile in each individual.
🌱 The Next Steps: Creating More Complex and Realistic Brain Models
The researcher Dr. Vassiliki Mascheraki plans to develop more advanced models that include immune cells and vascular-like networks, which may make the cultured models more representative of the real brain.
The advantages of these more complex models will be in providing a comprehensive view of the disease and its pathways within an environment resembling the living brain, thereby enhancing the possibility of designing more specialized and effective drugs based on the response of customized tissues.
🩺 Conclusion
This study represents an important advance in the field of scientific research and Alzheimer’s, as it opens the door to personalized medicine that relies on precise individual responses to different treatments.
The reliance on brain organoids made from real patient cells, along with monitoring extracellular vesicles, points to a promising scientific future for improving understanding of Alzheimer’s disease and developing precisely tailored therapeutic strategies.
And although these results are considered an initial step, developing and improving these models may help overcome the challenges posed by variation in patient responses, which is a fundamental goal in neurological medicine research.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
